Compare OBDC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBDC | GKOS |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.9B |
| IPO Year | 2015 | 2015 |
| Metric | OBDC | GKOS |
|---|---|---|
| Price | $11.60 | $118.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $14.28 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 7.7M | 705.7K |
| Earning Date | 04-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 13.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.29 |
| Revenue Next Year | N/A | $27.74 |
| P/E Ratio | $9.31 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $10.70 | $73.16 |
| 52 Week High | $15.36 | $130.23 |
| Indicator | OBDC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 51.87 |
| Support Level | $11.15 | $79.71 |
| Resistance Level | $14.67 | $130.23 |
| Average True Range (ATR) | 0.44 | 5.31 |
| MACD | 0.03 | 0.44 |
| Stochastic Oscillator | 51.34 | 74.50 |
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.